Autopsy report · NCT03571828

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

“Amgen decided to discontinue study because of a business decision and not because of safety reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 3 years 2 months before it stopped.
• 10 participants enrolled.
• Results were posted on the registry 2 years 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Amgen

Sponsor type

Industry

Conditions

Diffuse Large B-cell Lymphoma(DLBCL); Mantle Cell Lymphoma (MCL); Follicular Lymphoma (FL)

Interventions

AMG 562

Participants

10

Sites

12

Countries

Belgium, Canada, Germany, United States

Trials that died the same way

• Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)
  “A strategic decision was made to discontinue the study. The decision was not based on a safety concern.” (71% match in meaning)
• A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
  “Business decision to stop the study.” (70% match in meaning)
• Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
  “Amgen decided to terminate the study early to be able to meet US regulatory timelines fo filing. Subjects in treatment were rolled over to the 20140159 study.” (70% match in meaning)
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy
  “Study was withdrawn due to scientific and business considerations.” (70% match in meaning)
• Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab
  “AMGEN, due to a change in priorities within the Tarlatamab programme, has decided to withdraw its support for the study, which means the clinical trial will be terminated early.” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.